Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 4/2022

01.11.2022 | short review

ASCO 2022 update: (neo-)adjuvant treatment of colorectal cancer

verfasst von: Dr. Gudrun Piringer, MSc

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Summary

In this short review, two late breaking abstracts of neoadjuvant and adjuvant treatment concepts for colorectal cancer presented at ASCO 2022 will be highlighted. Both treatment concepts have the potential to change the standard of care in a subgroup of colorectal cancer patients in the future.
Literatur
1.
Zurück zum Zitat Sauer R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.CrossRef Sauer R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.CrossRef
2.
Zurück zum Zitat Bahadoer R, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (Rapido) a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;222:29–42.CrossRef Bahadoer R, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (Rapido) a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;222:29–42.CrossRef
4.
Zurück zum Zitat Cercek A, et al. Mismatch repair-deficient rectal cancer and resistance to neoadjuvant chemotherapy. Clin Cancer Res. 2020;26:3271–9.CrossRef Cercek A, et al. Mismatch repair-deficient rectal cancer and resistance to neoadjuvant chemotherapy. Clin Cancer Res. 2020;26:3271–9.CrossRef
5.
Zurück zum Zitat André T, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207–18.CrossRef André T, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207–18.CrossRef
6.
Zurück zum Zitat Overmann MJ, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36:773–9.CrossRef Overmann MJ, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36:773–9.CrossRef
7.
Zurück zum Zitat Cercek A, et al. PD‑1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Eng J Med. 2022;386:2363–76.CrossRef Cercek A, et al. PD‑1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Eng J Med. 2022;386:2363–76.CrossRef
8.
Zurück zum Zitat Sargent D, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27:872–7.CrossRef Sargent D, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27:872–7.CrossRef
9.
Zurück zum Zitat Tie J, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8:346.CrossRef Tie J, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8:346.CrossRef
10.
Zurück zum Zitat Tie J, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Eng J Med. 2022;386:2261–72.CrossRef Tie J, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Eng J Med. 2022;386:2261–72.CrossRef
Metadaten
Titel
ASCO 2022 update: (neo-)adjuvant treatment of colorectal cancer
verfasst von
Dr. Gudrun Piringer, MSc
Publikationsdatum
01.11.2022
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-022-00841-6

Weitere Artikel der Ausgabe 4/2022

memo - Magazine of European Medical Oncology 4/2022 Zur Ausgabe